Brain metastasis (BM) is the most common event in patients with lung cancer. Despite
multimodal treatments and advances in systemic therapies, development of BM remains one …

Purpose Treatment guidelines for advanced non–small-cell lung cancer (aNSCLC)
recommend broad molecular profiling for targeted therapy selection. This study …

Introduction: We report on the results of the German early access program (EAP) with the
third-generation ALK-and ROS1-inhibitor lorlatinib. Patients and Methods: Patients with …

Simple Summary Precision medicine is a revolutionary new way to deliver cancer treatment
by targeting specific genetic changes of the cancer of the individual child with the goal of …

Abstract Treatment of advanced non-small cell lung cancer (NSCLC) has radically improved
in the last years due to development and clinical approval of highly effective agents …

The use of targeted small-molecule therapeutics and immunotherapeutics has been limited
to date in pediatric oncology. Recently, the number of pediatric approvals has risen, and …

Tumour neoantigens arising from cancer-specific mutations generate a molecular fingerprint
that has a definite specificity for cancer. Although this fingerprint perfectly discriminates …

Since the discovery of targeted therapy with epidermal growth factor receptor (EGFR),
anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have been introduced as …

Background Inhibitors of the anaplastic lymphoma kinase (ALK) gene mutation are highly
effective treatments for ALK-positive lung cancer. We conducted this pharmacovigilance …

Comprehensive analysis of omics data, such as genome, transcriptome, proteome,
metabolome, and interactome, is a crucial technique for elucidating the complex mechanism …